Pfizer (NYSE:PFE) and Bristol Myers Squibb are making their blood thinner Eliquis available through the Mark Cuban Cost Plus ...

Pfizer (PFE) recently reported a revenue decline tied to weaker COVID product sales and a US$4.4b impairment charge, while ...

Track Pfizer share price today on NSE/BSE with real-time updates. Check stock performance, fundamentals, market cap, shareholding, financial reports, annual & quarterly results, and profit & loss ...

Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Pfizer’s monthly GLP-one obesity candidate and broad clinical program add fresh attention to its healthcare pipeline and long ...

Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or ...

During periods of uncertainty, investors often pay closer attention to businesses that look built to withstand the noise.

Pfizer is seeking drug development partnerships with Chinese biotech companies as local players gain ground on Western peers. The company aims to broaden its research and development model beyond the ...

Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...